A Propensity Score Matched Study Supports the Use of Allogeneic HSCT in Advanced-Stage, High-Risk Cutaneous T-Cell Lymphomas
Findings from the CUTALLO study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
EMA Recommends Extension of Indications for Nivolumab and Ipilimumab
Extended indication concerns the treatment of melanoma in adolescents 12 years of age and older
Favourable Benefit-Risk Profile of Trastuzumab Deruxtecan in Patients with HER2-positive MBC Who were Previously Treated with Trastuzumab Emtansine
Findings from the DESTINY-Breast02 study
A Combination of Trifluridine-Tipiracil Plus Bevacizumab Results in Longer Overall Survival Among Patients with Refractory mCRC
Findings from the SUNLIGHT study
Temporary Interruption of Adjuvant Endocrine Treatment to Attempt Pregnancy Does Not Increase Short-Term Risk for Worsening Breast Cancer Outcomes
Findings from the POSITIVE study
EMA Recommends Granting a Conditional Marketing Authorisation for Pirtobrutinib
It is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma who have been previously treated with a Bruton’s tyrosine kinase inhibitor
Initial Results of the CanScreen5, an Authentic Data Repository for Cancer Screening Globally
Substantial heterogeneity observed in cancer screening programme organisation and performance
Adagrasib Demonstrates Clinical Activity Across a Broad Range of Tumour Types in Patients with Unresectable or Metastatic Solid Tumours Harbouring a KRASG12C Mutation
Findings from the KRYSTAL-1 study cohort excluding NSCLC and CRC
Treatment Benefit with Quizartinib, a Potent and Specific FLT3 Inhibitor for Patients with FLT3-ITD-Positive Newly Diagnosed AML
Findings from the QuANTUM-First study
EMA Recommends Granting a Conditional Marketing Authorisation for Futibatinib
It is intended for the second-line treatment of locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement
Patients Diagnosed with Cancer During Pregnancy May Have Increased Risk of Mortality, But Not All Cancer Sites Present the Same Risk
Findings from a large retrospective cohort study
FDA Approves Polatuzumab Vedotin-piiq for Previously Untreated Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, and High-Grade B-Cell Lymphoma
Evidence for efficacy is based on the results from the POLARIX study